Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print April 26, 2006, doi:10.1212/01.wnl.0000217916.00225.3a)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000217916.00225.3av1
01.wnl.0000217916.00225.3av2
66/11/1654    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glauser, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glauser, T. A.
Received April 28, 2005
Accepted February 22, 2006

Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures

T. A. Glauser MD*, R. Ayala MD, R. D. Elterman MD, W. G. Mitchell MD, C. B. Van Orman MD, L. J. Gauer BS, Z. Lu MD, PhD, on behalf of the N159 Study Group

From Children’s Hospital, Department of Neurology, Cincinnati, OH (T.A.G.); Tallahassee Neurology Clinic, Tallahassee, FL (R.A.); Dallas Pediatric Neurology Associates, Dallas, TX (R.D.E.); Childrens Hospital Los Angeles and Keck School of Medicine of University of Southern California, Los Angeles, CA (W.G.M.); Primary Children’s Medical Center, University of Utah, Salt Lake City, UT (C.B.V.O.); and UCB Inc., Atlanta, GA (L.J.G., Z.L.).


* To whom correspondence should be addressed. E-mail: glauser{at}cchmc.org.

Abstract-- Objective: To evaluate the efficacy and tolerability of levetiracetam (LEV) as adjunctive therapy in children (4 to 16 years) with treatment-resistant partial-onset seizures. Methods: This multicenter, randomized, placebo-controlled trial consisted of an 8-week baseline period followed by a 14-week double-blind treatment period. During the treatment period, patients received either placebo or LEV add-on therapy and were up-titrated to a target dose of 60 mg/kg/day. Results: One hundred ninety-eight patients (intent-to-treat population) provided evaluable data. The reduction in partial-onset seizure frequency per week for LEV adjunctive therapy over placebo adjunctive therapy was significant (26.8%; p = 0.0002; 95% CI 14.0% to 37.6%). A 50% or greater reduction of partial seizure frequency per week was attained in 44.6% of the LEV group (45/101 patients), compared with 19.6% (19/97 patients) receiving placebo (p = 0.0002). Seven (6.9%) LEV-treated patients were seizure-free during the entire double-blind treatment period, compared with one (1.0%) placebo-treated patient. One or more adverse events were reported by 88.1% of LEV-treated patients and 91.8% of placebo patients. The most common treatment-emergent adverse events were somnolence, accidental injury, vomiting, anorexia, hostility, nervousness, rhinitis, cough, and pharyngitis. A similar number of patients in each group required a dose reduction or withdrew from the study as a result of an adverse event. Conclusion: Levetiracetam adjunctive therapy administered at 60 mg/kg/day is efficacious and well tolerated in children with treatment-resistant partial seizures.




This article has been cited by other articles:


Home page
 J Child NeurolHome page
P. Krief, Li Kan, and J. Maytal
Efficacy of Levetiracetam in Children With Epilepsy Younger Than 2 Years of Age
J Child Neurol, May 1, 2008; 23(5): 582 - 584.
[Abstract] [PDF]

Home page
 NeurologyHome page
S. Noachtar, E. Andermann, P. Meyvisch, F. Andermann, W. B. Gough, J. Schiemann-Delgado, and For the N166 Levetiracetam Study Group
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures
Neurology, February 19, 2008; 70(8): 607 - 616.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. F. Berkovic, R. C. Knowlton, R. F. Leroy, J. Schiemann, U. Falter, and On behalf of the Levetiracetam N01057 Study Group
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy
Neurology, October 30, 2007; 69(18): 1751 - 1760.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D.G.A. Kasteleijn-Nolst Trenite, P. Genton, D. Parain, P. Masnou, B. J. Steinhoff, T. Jacobs, E. Pigeolet, A. Stockis, and E. Hirsch
Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model
Neurology, September 4, 2007; 69(10): 1027 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. Striano, A. Coppola, M. Pezzella, C. Ciampa, N. Specchio, F. Ragona, M. M. Mancardi, E. Gennaro, F. Beccaria, G. Capovilla, et al.
An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy
Neurology, July 17, 2007; 69(3): 250 - 254.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. J. Brodie, E. Perucca, P. Ryvlin, E. Ben-Menachem, H.-J Meencke, and for the Levetiracetam Monotherapy Study Group
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy
Neurology, February 6, 2007; 68(6): 402 - 408.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by AAN Enterprises, Inc.